Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 11/20 | 0.49 |
| ▸ | APOB | P04114 | 9/20 | 0.49 |
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | UGCG | Q16739 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793794 | 0.89 | BCL2 (0.41) | MTTPAPOBRXFP1GAAKDM4E | |
| SCHEMBL7085681 | 0.88 | MTTP (0.47) | MTTPAPOBSMORXFP1UGCG | |
| SCHEMBL7139254 | 0.88 | LMNA (0.50) | MTTPAPOBSMOLMNAHTT | |
| SCHEMBL6789234 | 0.87 | SMO (0.47) | MTTPAPOBSMORXFP1UGCG | |
| SCHEMBL6787835 | 0.87 | MTTP (0.47) | MTTPAPOBSMORXFP1UGCG | |
| SCHEMBL6792697 | 0.84 | MTTP (0.45) | MTTPAPOBSMORXFP1UGCG | |
| SCHEMBL6792205 | 0.83 | MTTP (0.47) | MTTPAPOBSMORXFP1UGCG | |
| SCHEMBL6787209 | 0.82 | PTGS1 (0.51) | MTTPAPOBSMOLMNAHTT | |
| SCHEMBL7085678 | 0.81 | MTTP (0.46) | MTTPAPOBSMORXFP1GAA | |
| SCHEMBL6498923 | 0.80 | APOB (0.43) | MTTPAPOBSMORXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | MTTP 363/4885APOB 1/4885SMO 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.